Company / Shareholders' Equity
MADRIGAL PHARMACEUTICALS, INC. Shareholders' Equity History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$602.7M
FY2025
5-year range
$196.1M / $754.4M
FY2021-FY2025
Trend
-20.1%
vs FY2024
Sector context
#81 of 213
Health Care
What the data says
At $603M, MADRIGAL PHARMACEUTICALS, INC.'s shareholders' equity ranks #81 of 213 in the Health Care sector. Shareholders' Equity has fluctuated over the past 10 years, ranging from $36M in FY2016 to $754M in FY2024.
Based on SEC 10-K filings.
$603M in FY2025 with a 5-year CAGR of +20.2%.
Improved from $405M to $603M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +45.1%
- 5-Year CAGR
- +20.2%
- 10-Year CAGR
- -
Sector benchmark
#81 of 213 in Health CareTop 38% of 213This company $602.7M Sector average $2.5B
▼
-76.4% below sector average
Key checks
Key Insights
- 5-year CAGR of +20.2%, indicating consistent growth.
- In FY2025, shareholders' equity decreased 20.1% year-over-year.
- Ranks #81 out of 213 companies in the Health Care sector.
- Peak shareholders' equity was recorded in FY2024.
Company context
Key Data Points
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $602.7M | -20.1% |
| FY2024 | $754.4M | +86.1% |
| FY2023 | $405.3M | +105.3% |
| FY2022 | $197.4M | +0.7% |
| FY2021 | $196.1M | -18.3% |
| FY2020 | $240.0M | -42.4% |
| FY2019 | $416.6M | -12.7% |
| FY2018 | $477.0M | +161.7% |
| FY2017 | $182.3M | +400.6% |
| FY2016 | $36.4M | +186.5% |
As of FY2025 · SEC 10-K · Updated Mar 29, 2026